NCT00498212View on ClinicalTrials.gov

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

October 31, 2008

Conditions
Hepatitis B
Interventions
BIOLOGICAL

1018 ISS-HBsAg-Single

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

BIOLOGICAL

1018 ISS-HBsAg-Double

Intramuscular (IM) injection at Day 0, Week 4 and Week 24

Trial Locations (3)

A1A 3R5

White Hills Medical Clinic, St. John's

B3H 1E7

QEII Health Sciences Centre, Halifax

H3T 1E2

SMBD - Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY

NCT00498212 - A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease | Biotech Hunter | Biotech Hunter